Urogen Pharma Ltd. - (URGN) closed at $27.65 on November 20, 2026, down 12.9% from the previous close, on volume of 2,330,224 shares (30-day average 1,381,299).
Data as of November 20, 2026.
20-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 16, 2026 | ITM Straddle or Synthetic | 20-Nov-2628 C : 28 P | 214 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 20, 2026. See the largest for 5, 30, 60 and 90 days
UroGen highlights 35% Q/Q ZUSDURI growth as FDA sets June 14, 2027 PDUFA date for UGN-103
Market Chameleon (Wed, 4-Nov 4:01 AM ET)
Globe Newswire (Wed, 4-Nov 8:00 AM ET)
UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
Globe Newswire (Tue, 3-Nov 8:00 AM ET)
Globe Newswire (Mon, 2-Nov 8:00 AM ET)
Globe Newswire (Wed, 28-Oct 8:00 AM ET)
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
Globe Newswire (Tue, 27-Oct 6:00 PM ET)
Globe Newswire (Mon, 19-Oct 8:00 AM ET)
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 4-Sep 8:00 AM ET)
UroGen Pharma to Present at Upcoming Investor Conferences
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
ZUSDURI Revenue Surges 73% at UroGen: New Patent Strengthens Long-Term Outlook
Market Chameleon (Wed, 5-Aug 7:48 AM ET)
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Urogen Pharma Ltd. - trades on the NASDAQ stock market under the symbol URGN.
As of November 20, 2026, URGN stock price declined to $27.65 with 2,330,224 million shares trading.
URGN has a beta of 1.52, meaning it tends to be more sensitive to market movements. URGN has a correlation of 0.12 to the broad based SPY ETF.
URGN has a market cap of $1.35 billion. This is considered a Small Cap stock.
Last quarter Urogen Pharma Ltd. - reported $89 million in Revenue and -$.03 earnings per share. This fell short of revenue expectation by $-255,688 and missed earnings estimates by -$.12.
In the last 3 years, URGN traded as high as $50.81 and as low as $3.42.
The top ETF exchange traded funds that URGN belongs to (by Net Assets): IWM, IWO, IBB, VTWO, FESM.
URGN has outperformed the market in the last year with a price return of +11.3% while the SPY ETF gained +6.9%. However, in the short term, URGN had mixed performance relative to the market. It has underperformed in the last 3 months, returning -40.9% vs -9.3% return in SPY. But in the last 2 weeks, URGN shares have fared better than the market returning +11.7% compared to SPY -6.2%.
URGN support price is $30.19 and resistance is $33.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that URGN shares will trade within this expected range on the day.